Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
55
resultados
Última actualización
04/11/2026 [08:08:00]
Resultados 50 a 55 de 55
Resumen de: US20260327279A1
0000 A HIP/PAP protein, or a derivative thereof, is provided for the treatment and prevention cognition conditions. In particular the HIP/PAP protein, or a derivative thereof is for the treatment of a cognitive disorder associated with anxiety disorder(s) in an individual in need thereof as well as for improving cognition in an individual affected by a neurological disorder associated with anxiety disorder(s). The HIP/PAP protein, or a derivative thereof is also alleviating cognitive deficit in an individual affected by a disorder selected from Obsessive-compulsive disorder, Attention deficit disorder, Dementia with Lewy bodies disease, Early onset dementia, Epilepsy-related cognitive dysfunction, Fronto-temporal dementia, Posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar disorder, substance abuse, attention deficit disorders, psychotic disorders and a sars-cov-2 infection, and also in the prevention and/or treatment of diet induced cognitive and anxiety deficits in an individual in need thereof, and in particular high fat diet induced cognitive and anxiety deficits.
Resumen de: US20260325583A1
0000 Disclosed are methods of treating amyotrophic lateral sclerosis in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.
Resumen de: US20260325670A1
0000 The invention provides a composition for delivering an active pharmaceutical ingredient (API) and/or active nutraceutical ingredient (ANI) to the basal ganglia of a subject in need thereof comprising a plurality of nanoparticles surface decorated with caffeine, wherein the nanoparticles comprising: at least one API or ANI, at least one emulsifier, at least one emulsifier stabilizer, at least one water miscible solvent, and at least one solid lipid matrix core; and a pharmaceutically or nutraceutically acceptable carrier. The invention further provides methods for delivering active ingredients to the to the basal ganglia of a subject in need thereof and methods for treating Parkinson's disease.
Resumen de: US20260325548A1
A method of reducing neuroinflammation, tau accumulation, tau phosphorylation, and/or corticosterone secretion to treat or prevent Alzheimer's disease or related dementias, depression, and/or anxiety in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Glucocorticoid receptor antagonists such as mifepristone and nanodendriplexes comprising RNA interference agents targeting FKBP5, IFI16, or a combination thereof exhibit efficacy in reducing abnormal tau accumulation and neuroinflammation in Cov-2-infected patients to reduce neurological symptoms associated with infection.
Resumen de: WO2026220298A1
Provided for are prodrugs of doxycycline. The prodrugs may be advantageously administered for the treatment of disease, including neurological and neurodegenerative diseases or disorders. Doxycycline prodrugs may have reduced antibiotic activity compared to doxycycline for improved pharmacological properties. Also provided for are methods of treating neurodegenerative diseases such as Parkinson's disease or an alpha synucleinopathy with the doxycycline prodrugs and pharmaceutical compositions thereof.
Resumen de: WO2026222314A1
The disclosure is directed, in part, to methods of treating a patient suffering from a neurodegenerative disease, e.g., Parkinson's disease, comprising administering to the patient and effective amount of a TYK2 inhibitor. In some embodiments, the patient has elevated myxovirus resistance protein 1 (MX1) gene or protein expression.
Resumen de: WO2026220933A1
Provided is a pharmaceutical composition that has fewer side effects and that makes it possible to obtain an effect of preventing or treating Parkinson's disease A pharmaceutical composition for preventing or treating Parkinson's disease according to an embodiment of the present invention contains a nucleic acid that inhibits the expression of Rap1GAP.
Resumen de: US20260325453A1
0000 Polydopamine-coated nanoparticles are presented as a novel composition for intracranial delivery, designed to absorb UV photons and mitigate neuroinflammation in brain tissue. These nanoparticles feature a core that includes materials such as silica, gold, iron oxide, or polymeric micelles and are encapsulated within a polydopamine shell. Additionally, biologically active agents can be incorporated to enhance neuroprotection. Methods are provided for treating neurodegenerative diseases (e.g., Parkinson's, Huntington's, ALS, Alzheimer's) or improving glioblastoma therapy by administering the polydopamine-coated nanoparticles directly to affected brain regions via intracerebral injection, intrathecal infusion, or convection-enhanced delivery. Furthermore, the polydopamine-coated nanoparticles hold potential for pharmaceutical applications in developing medicaments targeting neuroinflammation and UV photon absorption within the central nervous system.
Resumen de: US20260325476A1
0000 Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated linoleic acid or an ester thereof.
Resumen de: WO2025128781A1
Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.
Resumen de: WO2025128873A1
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
Resumen de: WO2025128848A1
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
Resumen de: WO2025125135A1
The invention provides new heterocyclic compounds having the general formula (I) wherein X, Y, A, B, C, and R1 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as soluble epoxide hydrolase inhibitors.
Resumen de: CN122422322A
Novel compounds of formula (I), and pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and are useful in the treatment, prevention, management, amelioration, control and inhibition of diseases mediated by NLRP3. The compounds of the invention are useful for treating, preventing or managing diseases, disorders and conditions mediated by NLRP3, such as, but not limited to, NLRP3. Obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's disease, Parkinson's disease, Lewy body dementia (DLB) and traumatic brain injury. (I).
Resumen de: WO2026215661A1
The present disclosure relates to the use of a bisphosphonate, specifically tiludronate, etidronate, clodronate, pamidronate, zoledronate, and combinations thereof, for the treatment of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, among others. Additionally, the disclosure encompasses a method for treating neurodegenerative disorders by administering an effective amount of a bisphosphonate to a subject in need thereof.
Resumen de: WO2026215248A1
The present invention concerns the treatment of neurodegenerative disorders and provides for novel treatments for such disorders, Alzheimer disease, Parkinson Disease and Amyotrophic Lateral Sclerosis in particular. It is also directed to novel therapeutic combinations useful for treating such disorders.
Resumen de: WO2026217520A1
The present disclosure provides methods and compositions for treating Amyotrophic Lateral Sclerosis (ALS) in a subject in need thereof. In certain embodiments, the method comprises administering to the subject an effective amount of a composition comprising a recombinant adeno-associated virus (AAV) vector comprising a nucleic acid encoding a trophic factor operably linked to a muscle-specific promoter. In certain embodiments, the trophic factor is Brain-Derived Neurotrophic Factor (BDNF). In certain other embodiments, the trophic factor is Growth Arrest-Specific 6 (GAS6).
Resumen de: WO2026217660A1
Compositions comprising a pharmaceutically effective amount of diamine oxidase (DAO) or a homolog thereof, for the generation of active polyamine metabolites in a subject in need thereof. The compositions may further optionally include one or more polyamines and/or one or more polyphenols. Senolytic compositions comprising DAO and tetramethoxyluteolin (TML) for selectively targeting and eliminating senescent cells are also provided. In certain embodiments, the disclosed compositions and methods of using the compositions are effective for the treatment or prevention of, among other conditions and disorders, inflammation and inflammation-related disorders, allergies and allergic reactions, mast cell disorders including MCAS, histamine intolerance, and various age-related disorders including Alzheimer's disease, Parkinson's disease, and systemic sclerosis. The Applicant has recognized that the beneficial effects of polyamine therapy are derived from polyamine metabolites generated through DAO-mediated enzymatic conversion, and that unmetabolized polyamines can activate mast cells via MRGPRX2, causing or exacerbating allergic and inflammatory states.
Resumen de: WO2026217497A1
The present disclosure relates to compounds that are capable of inhibiting PRMT8 and/or upregulating SirTl. The disclosure further relates to methods of treating neurodegenerative diseases and disorders (e.g., Alzheimer's disease) using such compounds.
Resumen de: WO2026217569A1
Methods and compositions for treating Alzheimer's disease and related neurodegenerative conditions using intranasal nose-to-brain delivery of ST266, an amnion-derived cell secretome are described. ST266 is a multi-component, acellular biologic composition produced from amnion-derived multipotent progenitor (AMP) cells under cGMP conditions and comprising a plurality of anti-inflammatory, neuroprotective, anti-apoptotic, and regenerative cytokines and growth factors. When administered intranasally, ST266 bypasses the blood-brain barrier and simultaneously targets multiple pathological mechanisms underlying Alzheimer's disease, including neuroinflammation, insulin dysregulation, oxidative stress, neuronal damage, and synaptic dysfunction. The invention encompasses pharmaceutical compositions formulated for intranasal nose-to-brain delivery, methods of treating Alzheimer's disease by administering such compositions, and methods of reducing neuroinflammation and improving insulin regulation in the central nervous system. The non-invasive nature of intranasal delivery offers significant advantages in patient compliance and minimization of systemic side effects.
Resumen de: WO2026217770A1
The disclosure provides compounds, in part, compounds of Formula I and their use in treating medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and methods of making compounds of the disclosure are provided. The compounds are contemplated to be modulators, e.g., inhibitors, of cyclic ADP ribose hydrolase (CD38).
Resumen de: WO2026215819A1
The present invention relates to the field of organic chemistry and drug design. Here, the present invention provides a novel substituted quinazolinone compound of formula I and a robust and reproducible method of preparation of the heterocyclic compound of formula I for the management of Alzheimer's disease. The method of synthesis comprises of formation of a heterocyclic intermediate of formula II through the preparation of a benzoic acid intermediate and metal free cyclization of the benzoic acid intermediate and further subjecting the heterocyclic intermediate of formula II to C–N bonding with substituted aromatic amines by Buckwald Hartwig reaction to yield the heterocyclic compound of formula I. Moreover, the present invention provides pure heterocyclic compound with higher yields with milder reaction conditions, environment friendly and cost-effective reactants and reagents for management of Alzheimer's disease.
Resumen de: US20260317296A1
0000 Provided are heterocyclic compounds of Formula I or Formula II or their pharmaceutically pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers for imaging tau aggregates. Compounds of Formula I or Formula II may be used for the detection of tau aggregates in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy.
Nº publicación: US20260317384A1 15/10/2026
Solicitante:
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
The Regents of the University Of California
Resumen de: US20260317384A1
0000 The disclosure provides humanin mimetics that increase neuronal p-AKT and enhance p-gp130 as a new therapeutic class for chronic diseases such as Alzheimer's disease.
BOPI
Sede Electrónica
